Analyst Sees Huge Upside For Arcadia Biosciences Stock

RDKA has been prone to making big moves this year

Jun 19, 2018 at 9:32 AM
facebook twitter linkedin

Agricultural biotech Arcadia Biosciences Inc (NASDAQ:RKDA) is again making a big move on the charts, after receiving its first analyst recommendation since going public roughly three years ago. H.C. Wainwright initiated coverage on RKDA stock with a "buy" rating and a stunning $20 price target, meaning it expects the shares to more than double, as they closed Monday at $8.16. The analyst in coverage suggested there are a number of potential catalysts that could boost RKDA, including the company's wheat program.

While the $20 price target certainly seems ambitious, it's far from uncharted territory for the security. In fact, Arcadia traded as high as $66.56 back in March, following the positive results for its wheat program. Since then it's struggled to gain upside momentum, however, hitting a near-term low of $7.31 about a month ago. In today's trading, RKDA shares are up 5.4% at $8.60.

But despite the stock's depressed price -- its 14-day Relative Strength Index (RSI) was 33 at yesterday's close -- many traders continue to bet against it. That's based on a dramatic 278.4% surge in short interest during the last two reporting periods. In fact, short interest on Arcadia Biosciences stock is at an all-time high.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners